摘要
目的系统评价雷公藤多苷(tripterygium glycosides,TG)对比肾素-血管紧张素-醛固酮系统(RAAS)阻滞剂治疗糖尿病肾脏病的有效性和安全性。方法检索CNKI、CBM、VIP、万方数据、Embase、Pubmed和Cochrane Library数据库;筛选文献,对数据进行Meta分析。结果检索得到14篇文献,纳入826名患者。Meta分析结果显示,TG组治疗糖尿病肾脏病的有效率优于RAAS阻滞剂组,且差异具有统计学意义[OR=3.91,95%CI(1.91,8.01),P=0.0002];TG组UP降低程度优于RAAS阻滞剂组,且差异具有统计学意义[MD=-0.53,95%CI(-0.77,-0.29),P<0.0001];TG组BUN降低程度优于RAAS阻滞剂组,且差异有统计学意义[MD=-2.20,95%CI(-2.79,-1.61),P<0.00001];TG组与RAAS阻滞剂组在降低Scr方面疗效相当,差异无统计学意义[MD=-5.47,95%CI(-11.04,-0.11),P=0.05];在不良反应上,TG组与RAAS阻滞剂组相当,差异无统计学意义[MD=1.01,95%CI(0.56,1.82),P=0.46]。结论TG治疗糖尿病肾脏病的总体疗效明显,对UP、BUN水平的降低效果优于RAAS阻滞剂,而在不良反应发生率上与RAAS阻滞剂相当。
Objective To evaluate the efficiency and safety of tripterygium glycosides(TG)in the treatment of diabetic kidney disease compared with RAAS blockers.Methods Meta-analysis of retrieved results and data was performed through CNKI,CBM,VIP,Wanfang data,Embase,Pubmed,and Cochrane Library databases.Results A total of 14 articles were retrieved,The results of efficiency showed that the TG group was better than the RAAS blocker group,with statistically significant difference[OR=3.91,95%CI(1.91,8.01),P=0.0002].The results of UP showed that decrease magnitude in the test group was lower than that in the control group,with statistically significant difference[MD=-0.53,95%CI(-0.77,-0.29),P<0.0001].The results of BUN showed that the BUN in the test group was lower than that in the control group,with statistically significant difference[MD=-2.20,95%CI(-2.79,-1.61),P<0.00001].The results of Scr showed that the result between test group and control group were equally effective,with no statistically significant difference[MD=-5.47,95%CI(-11.04,-0.11),P=0.05];with respect to adverse reactions,the test group was comparable to the control group,with no statistically significant difference[MD=1.01,95%CI(0.56,1.82),P=0.46].Conclusions The overall efficiency of TG in the treatment of diabetic kidney disease is significant.It has lower UP,BUN and Scr levels compared with RAAS blockers,while its adverse reaction incidence is comparable to that of RAAS blockers.
作者
朱国双
王岚
龙清华
金善善
孙龙
李颖霞
邓丹芳
林腊梅
王小琴
ZHU Guo-shuang;WANG Lan;LONG Qing-hua;JIN Shan-shan;SUN Long;LI ying-xia;DENG dan-fang;LIN La-mei;WANG xiao-qin(Hubei University of Traditional Chinese Medicine,Wuhan 430061,China)
出处
《临床肾脏病杂志》
2019年第10期727-733,共7页
Journal Of Clinical Nephrology
基金
国家自然科学基金面上项目(81874439)
国家自然科学基金面上项目(81573907)
